Description
Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspectives of nano-pharmacokinetics using cancer as a model disease. Nano-pharmacokinetics is emerging as an important sub discipline of nanoscience and medical sciences because of the increasing safety issues of nanosystems on living organisms. This book reports the dynamics of nanosystems in living organisms for better understanding of nanotoxicity, pharmacology, biochemistry, physiology and medicine perspectives. It further examines current progress of state-of-the art pharmacokinetics mechanisms, which will be of great help to develop more clinical-oriented nanosystems with a wide safety margin. The book is divided into three sections: the first section focuses on the concept of pharmacokinetics with state-of-the-art Nano-Pharmacokinetics (NPK). The second section looks at the engineering of nanoparticles and pharmacokinetics clinical development. The final section focuses on Nano-Pharmacokinetics and Theranostics, elaborating the basic question of how pharmacokinetics of nanomaterials relate to their end applications such as cancer therapy. Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy will be useful to researchers in the field of nanoparticle based targeted drug delivery including pharmaceutical scientists, material scientists, chemists, nanotechnologists, biomedical scientists, and clinicians.- Includes contributions from highly qualified scientists, regulatory entities, enterprises and medical practitioners to explain the long and inherently multidisciplinary pathway of nano-pharmacokinetics- Describes assessment methods of nano-pharmacokinetics- Examines the interface between nanomedicine and pharmacokinetics to diagnose and treat cancer
Table of Contents
Section I: Nano-Pharmacokinetics Current state of the art 1. Introduction 2. Nano-Pharmacokinetics (NPK): Current state of the art 3. Engineered Nanomaterials and PharmacokineticsSection II: Nano-Pharmacokinetics Clinical development 4. Nano-Pharmacokinetics: Bio distribution and toxicology 5. Biological systems and Nano-Pharmacokinetics 6. Nano-Pharmacokinetics AssessmentSection III: Nano-Pharmacokinetics and cancer 7. Clinical significance of nanomaterials in cancer treatment 8. Nano-Pharmacokinetics and Theranostics: Co relation 9. Nano-Pharmacokinetics key role in cancer theranostics 10. Nano-Pharmacokinetics key role in in vivo imaging Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship 11. Nano-Pharmacokinetics Preclinical to Clinical Translation 12. Current pre-clinical stage of Nano-Pharmacokinetics 13. Advances in Clinical translation of Nano-Pharmacokinetics 14. Future Outlook and Conclusion
